Barclays Cuts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $56.00

Collegium Pharmaceutical (NASDAQ:COLL) had its target price lowered by Barclays from $58.00 to $56.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Barclays‘s price objective would suggest a potential upside of 22.05% from the company’s previous close.

A number of other research firms have also recently issued reports on COLL. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Truist Financial set a $55.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective (up previously from $46.00) on shares of Collegium Pharmaceutical in a research note on Friday. Finally, Needham & Company LLC raised their target price on shares of Collegium Pharmaceutical from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $52.80.

Collegium Pharmaceutical Price Performance

COLL traded down $2.90 during trading on Friday, hitting $45.88. 66,260 shares of the stock traded hands, compared to its average volume of 474,577. The business has a 50 day moving average price of $46.04 and a 200 day moving average price of $38.38. The company has a debt-to-equity ratio of 2.71, a current ratio of 1.36 and a quick ratio of 1.27. Collegium Pharmaceutical has a twelve month low of $23.23 and a twelve month high of $50.79. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 28.85 and a beta of 0.60.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The company had revenue of $135.55 million for the quarter. Equities research analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Insider Activity

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the sale, the chief financial officer directly owned 126,667 shares of the company’s stock, valued at $5,133,813.51. The trade was a 19.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Rita J. Balice-Gordon sold 3,650 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $47.03, for a total transaction of $171,659.50. Following the completion of the transaction, the director owned 52,629 shares of the company’s stock, valued at approximately $2,475,141.87. This trade represents a 6.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 51,250 shares of company stock valued at $2,235,352 over the last quarter. 2.51% of the stock is owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

Institutional investors have recently modified their holdings of the business. GAMMA Investing LLC increased its holdings in Collegium Pharmaceutical by 9.6% in the fourth quarter. GAMMA Investing LLC now owns 3,262 shares of the specialty pharmaceutical company’s stock valued at $151,000 after purchasing an additional 285 shares during the period. JPMorgan Chase & Co. lifted its holdings in Collegium Pharmaceutical by 193.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 211,757 shares of the specialty pharmaceutical company’s stock worth $7,409,000 after buying an additional 139,689 shares during the period. Tudor Investment Corp ET AL bought a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at about $560,000. NewEdge Advisors LLC increased its stake in shares of Collegium Pharmaceutical by 535.9% in the third quarter. NewEdge Advisors LLC now owns 19,376 shares of the specialty pharmaceutical company’s stock valued at $678,000 after buying an additional 16,329 shares during the period. Finally, Caxton Associates LLP acquired a new stake in shares of Collegium Pharmaceutical in the third quarter valued at about $961,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.